BioMedNewsBreaks

FridayNov 28, 2025 2:29 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. An article discussing this reads, “Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C, a capability that could transform global outbreak response readiness. The company’s publication, titled ‘Development of Thermostable Filovirus Vaccines Using Protein Subunit Technology,’ outlines preclinical data showing that the company’s filovirus vaccine antigens, formulated with its proprietary ThermoVax(R)…

Continue Reading

WednesdayNov 26, 2025 3:52 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Announces $15 Million Registered Direct Offering 

Nano-X Imaging (NASDAQ: NNOX) entered a securities purchase agreement with a single institutional investor to sell 3,826,530 ordinary shares in a registered direct offering expected to generate approximately $15 million in gross proceeds, with Titan Partners Group, a division of American Capital Partners, serving as sole placement agent. Closing is expected on or about Nov. 25, 2025, and the company plans to use the net proceeds for working capital and general corporate purposes. To view the full press release, visit https://ibn.fm/T8nKT About Nano-X Imaging Ltd. Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by…

Continue Reading

TuesdayNov 25, 2025 1:27 pm

BioMedNewsBreaks — Branded Legacy, Inc. (OTC: BLEG) Reports $125,000 Q3 Revenue from Pau Hana as Company Expands Kava Bar Growth Strategy 

Branded Legacy (OTC: BLEG), a provider of addiction treatment and harm-reduction solutions, reported third quarter revenue of just over $125,000 from its newly acquired Pau Hana subsidiary, a cash-flow-positive kava bar in West Melbourne, Florida. The company said Pau Hana’s strong daily retail performance provides a stable new revenue pillar and will serve as the blueprint for an aggressive 2026 expansion, including plans to open three to five new Florida locations and pursue additional acquisitions of profitable kava bars. Branded Legacy aims to build a scalable roll-up platform that layers centralized sourcing, branding and operational efficiencies across acquired venues, positioning the…

Continue Reading

MondayNov 24, 2025 9:40 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Chairman Presentation at NobleCon21

Nutriband (NASDAQ: NTRB) announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets’ annual emerging growth equity conference, on Dec. 3 at 9:30 a.m. Eastern at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida. Investors and guests may attend at a discounted rate using code NTRBNOBLECON, and a high-definition webcast will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days. To view the full press release, visit https://ibn.fm/CqOt4 About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our…

Continue Reading

MondayNov 24, 2025 9:00 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Engages NE Holdings to Guide Nasdaq Listing Strategy

HealthLynked (OTCQB: HLYK) said it has entered a Capital Market Advisory Agreement with “NE Holdings LLC,” a Florida-based consulting firm focused on senior exchange readiness and capital markets strategy, to support the Company plan to uplist to Nasdaq in the first half of 2026. NE Holdings will lead corporate and financial readiness efforts, oversee audit and compliance planning, assist with capital structure optimization, coordinate introductions to investment banks and key market participants, and advise on governance as HealthLynked advances its Nasdaq listing roadmap and broader public-market expansion strategy. To view the full press release, visit https://ibn.fm/ZxSyM About HealthLynked Corp. HealthLynked…

Continue Reading

FridayNov 21, 2025 9:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends

Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how fair-value remeasurements under GAAP are becoming key indicators of real scientific and commercial progress in late-stage biotech pipelines. The piece notes that Oncotelic is preparing for a significant fair-value remeasurement of its 45% stake in JV entity GMP Bio following a new independent valuation suggesting a potential step-up in asset value, reinforcing the company’s position as it advances its oncology efforts. To view the full press release, visit https://ibn.fm/YS5OI About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Continue Reading

ThursdayNov 20, 2025 11:28 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Preliminary $1.7B Pipeline Valuation From Joint Venture Partner 

Oncotelic Therapeutics (OTCQB: OTLC) today announced that joint venture partner GMP Bio has received an independent Frost & Sullivan (Hong Kong) valuation estimating the potential value of its therapeutic pipeline at approximately $1.7 billion, implying about $765 million for Oncotelic’s 45% stake. The non-binding, forward-looking analysis does not represent fair value under U.S. GAAP, and Oncotelic has initiated a separate ASC-compliant valuation that will support future financial reporting. Depending on the results, the Company may record a higher carrying value for its minority interest in upcoming periods, consistent with applicable fair-value measurement standards. CEO Dr. Vuong Trieu said the valuation…

Continue Reading

WednesdayNov 19, 2025 12:50 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised in the Future of Cardiac Care with Breakthrough Technology

HeartBeam (NASDAQ: BEAT) is on the verge of transforming how atrial fibrillation (“AF”) is detected and managed with its cable-free ECG technology. A recent article discussing this reads, “HeartBeam has developed a credit card-sized device and proprietary synthesis software that can capture heart signals in three dimensions and convert them into a full synthesized 12-lead ECG. By bringing clinical -grade cardiac diagnostics into the hands of patients wherever they are, HeartBeam is positioning itself at the forefront of a revolution in heart health, one that could greatly impact lives, reduce costs, and redefine the future of cardiac care.” To view…

Continue Reading

WednesdayNov 19, 2025 9:42 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases with unmet medical need, completed enrollment of the 50 patients required for the interim analysis in its 80-patient confirmatory Phase 3 FLASH2 study evaluating HyBryte (TM) in cutaneous T-cell lymphoma. The interim analysis is slated for the second quarter of 2026, with topline data expected in the second half of the year. The Company noted an overall blinded response rate of 48 percent among patients who have completed treatment to date, exceeding the anticipated 25 percent rate used in the study’s powering assumptions. Investigators report safety findings consistent…

Continue Reading

MondayNov 17, 2025 11:05 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study 

CNS Pharmaceuticals (NASDAQ: CNSP) reported third-quarter 2025 results and highlighted continued progress with TPI 287, its blood-brain barrier–permeable abeotaxane in development for glioblastoma and other CNS tumors. The Company noted Phase 1 data showing potential BBB penetration and tumor responses, including 3 complete and 9 partial responses among 23 evaluable patients treated with TPI 287 plus bevacizumab, and plans to engage the FDA early next year on a registration-focused Phase 2 trial design in recurrent GBM. For the quarter, CNS reported a net loss of $3.3 million, R&D expenses of $2.2 million and G&A expenses of $1.1 million, ending the…

Continue Reading